

Schwerpunkt: Akute Leukämien und MDS

Akute lymphoblastische Leukämien im Kindes- und Jugendalter – Eine Erfolgsgeschichte der Medizin (S. 10–23)

A. Attarbaschi, G. Mann

1. Pui CH, Evans WE Treatment of acute lymphoblastic leukemia. *N Engl J Med* 2006; 354: 166–178
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. *N Engl J Med* 2004; 350: 1535–1548
3. Stanulla M, Bourquin JP. Treatment of acute lymphoblastic leukemia in childhood: state of things and outlook for the future. *Pharm Unserer Zeit* 2012; 41: 203–213
4. Pieters R. Infant acute lymphoblastic leukemia: Lessons learned and future directions. *Curr Hematol Malig Rep* 2009; 4: 167–174
5. Schrappe M, Möricke A, Attarbaschi A, et al. Akute lymphoblastische Leukämien. In: Niemeyer C, Eggert A (Hrsg) *Pädiatrische Hämatologie und Onkologie*. Springer, Heidelberg, 2018; S 269–291
6. van der Does-van den Berg A, Bartram CR, Basso G, et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the “BFM Family” Cooperative Group. *Med Pediatr Oncol* 1992; 20: 497–505
7. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). *Leukemia* 1995; 9: 1783–1786
8. Campana D. Determination of minimal residual disease in leukaemia patients. *Br J Haematol* 2003; 121: 823–838
9. Mullighan C. The molecular genetic makeup of acute lymphoblastic leukemia. *Hematology Am Soc Hematol Educ Program* 2012; 389–396
10. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. *J Clin Invest* 2012; 122: 3398–3406
11. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. *Lancet Oncol* 2012; 13: 936–945
12. Mann G, Cazzaniga G, van der Velden VH, et al. Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The ‘big sister’ of the infant disease? *Leukemia* 2007; 21: 642–646
13. Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. *J Clin Invest* 2012; 122: 3407–3415
14. Moorman AV, Richards SM, Martineau M, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. *Blood* 2003; 102: 2756–2762
15. Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. *Blood* 2007; 110: 1112–1115
16. Gaynon PS. Prognostic factors in acute lymphoblastic leukemia. *J Pediatr Hematol Oncol* 2000; 22: 403–404

17. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOPBFM ALL 2000 study. *Blood* 2010; 115: 3206–3214
18. Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. *Blood* 2011; 118: 2077–2084
19. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. *Blood* 2008; 111: 4477–4489
20. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. *Lancet* 2007; 370: 240–250
21. Burger B, Beier R, Zimmermann M, et al. Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. *Pediatr Blood Cancer* 2005; 44: 220–225
22. Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. *Leukemia* 2000; 14: 2193–2194
23. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALLBFM 90. German-Austrian-Swiss ALL-BFM Study Group. *Blood* 2000; 95: 3310–3322
24. Schrauder A, Reiter A, Gadner H, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. *J Clin Oncol* 2006; 24: 5742–5749
25. Peters C, Schrauder A, Schrappe M, et al. Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. *Bone Marrow Transplant* 2005; 35 Suppl 1: S9–11
26. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALLBFM 86. *Blood* 1994; 84: 3122–3133
27. Riehm H, Reiter A, Schrappe M, et al. [Corticosteroiddependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. *Klin Padiatr* 1987; 199: 151–160
28. Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. *N Engl J Med* 2012; 366: 1371–1381
29. Moricke A, Zimmermann M, Reiter A, et al. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. *Leukemia* 2010; 24: 265–284
30. Dordelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. *Leukemia* 1998; 12: 645–651
31. Moricke A, Zimmermann M, Reiter A, et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. *Klin Padiatr* 2005; 217: 310–320

32. Locatelli F, Schrappe M, Bernardo ME, et al. How I treat relapsed childhood acute lymphoblastic leukemia. *Blood* 2012; 120: 2807–2816
-

Diagnostik und Therapie bei Myelodysplastischen Syndromen – Ein Update (S. 24–36)

K. Sockel, U. Platzbecker

1. Ma X, Does M, Raza et al. Myelodysplastic syndromes: incidence and survival in the United States. *Cancer* 2007; 109: 1536–1542
2. Papaemmanuil E, Gerstung M, Malcovati L et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood* 2013; 122(22): 3616–27
3. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. *Br J Haematol* 1982; 51: 189–199
4. Vardiman JW, Harris NL, Brunning RD et al. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood* 2002; 100(7): 2292–302
5. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood* 2009; 114(5): 937–51
6. Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016; 127: 2391–2405
7. Greenberg PL, Tüchler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood* 2012; 120: 2454–2465
8. Valent P, Horny H-P, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference. *Leuk Res* 2007; 31: 727–36
9. Valent P, Horny H-P. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. *Eur J Clin Invest* 2009; 39(7): 548–53
10. Della Porta MG, Malcovati L, Boveri E et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. *J Clin Oncol* 2009; 27(5): 754–762
11. Olney HJ, Le Beau MM et al. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. *Leuk Res* 2007; 31: 427–434
12. Schanz J, Tüchler H, Solé F et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. *J Clin Oncol* 2012; 30: 820–829
13. Elene C, Galli A, Such E et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic. *Blood* 2016 Sep 8; 128(10): 1408–1417
14. Platzbecker U, Germing U, Götze K et al. Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study. *Lancet Oncol* 2017 Oct; 18(10): 1338–1347
15. Fenaux P, Platzbecker U, Mufti GJ et al. The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Presented at the ASH Annual Meeting 2018, Dec 2,, San Diego, USA.

16. Kantarjian H et al. Romiplostim in low/int-1-risk MDS results in reduced bleeding without impacting leukemic progression: final results from a randomized, double-blind, placebo-controlled study. Oral presentation at the 14th International Symposium on Myelodysplastic Syndromes, Valencia, May 2017
17. Platzbecker U, Kubasch AS, Giagounidis A et al. Biomarkers of Response to Romiplostim in Patients with lower-risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia-Results of the EUROPE Trial by the EMSCO network. Presented at the ASH Annual Meeting 2019, Dec 7–10, Orlando, FL/USA
18. Angelucci E, Li j, Greenberg PL et al. Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int- 1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telecto Study. Presented at the ASH Annual Meeting 2018, Dec 1, San Diego, USA
19. List A, Kurtin S, Roe DJ et al. Efficacy of lenalidomide in myelodysplastic syndromes. *N Engl J Med* 2005; 352: 549–557
20. Jädersten M, Saft L, Smith A et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. *J Clin Oncol* 2011 May 20; 29(15): 1971–9
21. Platzbecker U. Treatment of MDS. *Blood* 2019 Mar 7; 133(10): 1096–1107
22. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. *J Clin Oncol* 2002; 20: 2429–2440
23. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol* 2009; 3: 223–232
24. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. *Leukemia* 2011; 25(7): 1147–1152
25. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. *Blood* 2014; 124(17): 2705–2712
26. Prebet T, Gore SD, Esterni B et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. *J Clin Oncol* 2011; 29(24): 3322–3327
27. Jabbour E, Garcia-Manero G, Batty N et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. *Cancer* 2010; 116(6): 3830–3834
28. DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. *Lancet Oncol* 2018; 19(2): 216–228
29. Garcia-Manero G et al. CC-486 (oral azacitidine) induces responses in patients with hematological malignancies who had failed prior treatment with injectable hypomethylating agents (HMAS). Oral presentation at the 14th International Symposium on Myelodysplastic Syndromes, Valencia, May 2017
30. Deeg HJ, de Lima M. Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. *J Natl Compr Canc Netw* 2013; 11(10): 1227–1233
31. Kroeger N, Sockel K, Wolschke Ch et al. Prospective Multicenter Phase 3 Study Comparing 5-Azacitidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55–70 years, the VidazaAllo Study). Presented at the ASH Annual Meeting 2018, Dec 1, San Diego, USA

32. de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. *Blood* 2017; 129: 1753–1762
33. Schroeder T, Wegener N, Lauseker M, et al. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia. *Biol Blood Marrow Transplant* 2019 Aug; 25(8): 1550–1559
34. Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). Presented at: 58th ASH Annual Meeting and Exposition; San Diego, California; Dec 2–6, 2016. Abstract 343
35. Stein EM, DiNardo CD, Altman JK, et al. Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. *Blood* 2015; 126(23): 323
36. Yang H. et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. *Leukemia* 2014; 28, 1280–1288
37. Sallman D, Dezern A, Sweet K, et al. Phase 1B/2 combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Abstract #S1558. Presented at the 23rd Congress of the European Hematology Association, June 17, 2018; Stockholm, Sweden
38. Maslah N, Salomao N, Drevon L et al. Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia *Haematologica* 2019 Sep 5
39. Steensma DP, Bejar R, Jaiswal S, et al.: Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood* 2015; 126: 9–16
40. Malcovati L, Galli A, Travaglino E et al. Clinical significance of somatic mutation in unexplained blood cytopenia. *Blood*. 2017; 129(25): 3371
41. Jaiswal S, Natarajan P, Silver A. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. *N Engl J Med* 2017; 377: 111–121

Dosisindividualisierung in der oralen Tumorthherapie – Modellunterstütztes Drugmonitoring und minimalinvasive Methoden (S. 43–50)

N. Isberner, H. Klinker, O. Scherf-Clavel

1. Lemmon MA, Schlessinger J, Cell. Signaling by Receptor Tyrosine Kinases. *Cell* 2010; 141: 1117–1134
2. Lipp H-P. Wechselwirkungsrisiken mit zielgerichtet wirksamen, niedermolekularen Arzneistoffen in der klinischen Onkologie. *Arzneimitteltherapie* 2019; 37: 200–210
3. van Leeuwen RWF, van Gelder T, Mathijssen RHJ, et al. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. *Lancet Oncol* 2014; 15: E315–E326
4. McCue DA, Lohr LK, Pick AM. Improving Adherence to Oral Cancer Therapy in Clinical Practice. *Pharmacotherapy* 2014; 34: 481–494
5. Gao B, Yeap S, Clements A, et al. Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. *J Clin Oncol* 2012; 30: 4017–4025

6. Herviou P, Thivat E, Richard D, et al. Therapeutic drug monitoring and tyrosine kinase inhibitors. *Oncol Lett* 2016; 12: 1223–1232
 7. European Medicines Agency. Giotrif – European Public Assessment Report (EPAR). Verfügbar unter: https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf
 8. European Medicines Agency. Cabometyx – European Public Assessment Report (EPAR). Verfügbar unter: https://www.ema.europa.eu/en/documents/product-information/cabometyx-epar-product-information_en.pdf
 9. European Medicines Agency. Tagrisso – European Public Assessment Report (EPAR). Verfügbar unter: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf
 10. European Medicines Agency. Tafinlar – European Public Assessment Report (EPAR). Verfügbar unter: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf
 11. European Medicines Agency. Mekinist – European Public Assessment Report (EPAR). Verfügbar unter: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf
 12. European Medicines Agency. Tasigna – European Public Assessment Report (EPAR). Abgerufen am: 22.08.2019; Verfügbar unter: https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf
 13. Groenland SL, Mathijssen RHJ, Beijnen JH, et al. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. *Eur J Clin Pharmacol* 2019; 75: 1309–1318
 14. de Wit D, Guchelaar HJ, den Hartigh J, et al. Individualized dosing of tyrosine kinase inhibitors: are we there yet? *Drug Discov Today* 2015; 20: 18–36
 15. Yu HX, Steeghs N, Nijenhuis CM, et al. Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets. *Clin Pharmacokinet* 2014; 53: 305–325
 16. Lankheet NAG, Desar IME, Mulder SF, et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. *Brit J Clin Pharmacol* 2017; 83:2195–2204
 17. Josephs DH, Fisher DS, Spicer J, et al., Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Implications for Therapeutic Drug Monitoring. *Ther Drug Monit* 2013; 35: 562–587
 18. Verheijen RB, Yu HX, Schellens JHM, et al., Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. *Clin Pharmacol Ther* 2017; 102: 765–776
 19. Giles FJ, Yin OQP, Sallas WM, et al. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. *Eur J Clin Pharmacol* 2013; 69: 813–823
 20. R Core Team, R: A Language and Environment for Statistical Computing 2019; <https://www.R-project.org/>
 21. Baron K, mrgsolve: Simulate from ODE-Based Population PK/PD and Systems Pharmacology Models 2019; <https://mrgsolve.github.io/>
 22. Larson RA, Yin OQP, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase. *Eur J Clin Pharmacol* 2012; 68: 723–733
 23. daGama. Abgerufen am: 22.08.2019; Verfügbar unter: <http://osc-lab.de/>
-

Update: Immunonkologische Therapien des lokal fortgeschrittenen und metastasierten Nierenzellkarzinoms (S. 51–54)

M. J. P. Hennig, M. Klee, M. W. Kramer

1. Cohen HT, McGovern FJ. Renal-Cell Carcinoma. *N Engl J Med* 2005; 353(23): 2477–2490
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA: A Cancer Journal for Clinicians*. 2018; 68(1): 7–30
3. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. *N Engl J Med* 2007; 356(2): 115–124
4. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma. *JCO* 1999; 17(8): 2530–2530
5. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. *Lancet Oncol* 2013; 14(2): 141–148
6. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2018; 378(14): 1277–1290
7. Lalani A-KA, McGregor BA, Albiges L, et al. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. *Eur Urol* 2019; 75(1): 100–110
8. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019; 380(12): 1116–1127
9. Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. *Eur Urol* 2019; 76(2): 151–156
10. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019; 380(12): 1103–1115
11. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. *The Lancet* 2019; 393(10189): 2404–2415
12. Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. *The Lancet Oncology* 2019; 20(5): 711–718
13. Grünwald V, Powles T, Choueiri TK, et al. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale. *Fut Oncol* 2019; 15(9): 929–941
14. Nadal RM, Mortazavi A, Stein M, et al. Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. *JCO* 2018; 36(6_suppl): 515–515
15. Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma. *Xelixis* May 2019. <http://ir.exelixis.com/news-releases/news-release-details/exelixis-initiating-phase-3-pivotal-trial-cosmic-313>. Accessed July 15, 2019

16. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial. *The Lancet* 2016; 387(10032): 2008–2016
17. Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. *JCO* 2017; 35(35): 3916–3923
18. Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: Results from the phase III, randomized ATLAS trial. *Ann Oncol* 2018; 29(12): 2371–2378
19. Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564). July 2019. <https://clinicaltrials.gov/ct2/show/NCT03142334>. Accessed July 15, 2019
20. A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion10). July 2019. <https://clinicaltrials.gov/ct2/show/NCT03024996>. Accessed July 15, 2019
21. A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914). June 2019. <https://clinicaltrials.gov/ct2/show/NCT03138512>. Accessed July 15, 2019
22. Patel HD, Puligandla M, Shuch BM, et al. The future of perioperative therapy in advanced renal cell carcinoma: How can we PROSPER? *Fut Oncol* 2019; 15(15): 1683–1695
23. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial. *Lancet Oncol* 2015; 16(15): 1473–1482
24. Motzer RJ, Ravaud A, Patard J-J, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. *Eur Urol* 2018; 73(1): 62–68

PHARMAFORUM:

Therapie des metastasierten Nierenzellkarzinoms (RCC): Studien belegen überlegene Wirksamkeit von Cabozantinib in der Zweitlinie (S. 65)

1. <https://www.onkopedia.com/de/onkopedia/guidelines/nierenzellkarzinom-hypernephrom/@@guideline/html/index.html>; aufgerufen am 26.9.2019
2. Fachinformation Cabometyx, Stand 11/2018
3. Choueri TK, et al. *Lancet Oncol* 2016; 17: 917–927
4. Motzer RJ, et al. *Br J Cancer* 2018; 118(9): 1176–8
5. Amzal B, et al. *PLOS one* 2017; 12(9): e0184423
6. Procopio G, et al. *Clin Genitourinary Cancer* 2018; 16(4): e945–51
7. Escudier B, et al. *Ann Oncol* 2019; 30:706-720
8. Albiges L, et al. *Eur Urol* 2019; 75(5):799-810
9. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Kidney Cancer; Version 1.2020, Juni 7, 2019